Skip to main content

Clinical characteristics, management, and outcomes of pulmonary valve myxoma: systematic review of published case reports



Cardiac myxoma is the most common type of primary cardiac tumor, with the majority located in the atrial wall. The tumor is attached to valvular structures in a few cases, of which the pulmonary valve is the least affected. Pulmonary valve myxoma may have different clinical manifestations from the more common cardiac myxomas because of its vital position. A misdiagnosis of these types of cardiac myxoma may be detrimental to the care and well-being of patients. Therefore, this systematic review aims to define the clinical characteristics of pulmonary valve myxoma and how this differs from a more common cardiac myxoma.


Employed literature was obtained from PubMed, ScienceDirect, Scopus, Springer, and ProQuest without a publication year limit on August 23, 2022. The keyword was “pulmonary valve myxoma.” Inclusion criteria were as follows: (1) case report or series, (2) available individual patient data, and (3) myxoma that is attached to pulmonary valve structures with no evidence of metastasis. Non-English language or nonhuman subject studies were excluded. Johanna Briggs Institute checklists were used for the risk of bias assessment. Data are presented descriptively.


This review included 9 case reports from 2237 articles. All cases show a low risk of bias. Pulmonary valve myxoma is dominated by males (5:4), and the patient’s median age is 57 years with a bimodal distribution in pediatric and geriatric populations. The clinical manifestation of pulmonary valve myxoma is often unspecified or asymptomatic. However, systolic murmur in the pulmonary valve area is heard in 67% of cases. Echocardiography remains the diagnostic modality of choice in the majority of cases. Tumor attached to the pulmonary cusps or annulus and extended to adjacent tissues in all cases. Therefore, valve replacement or adjacent tissue reconstructions are required in 77% of cases. The recurrence and mortality are considerably high, with 33% and 22% cases, respectively.


Pulmonary valve myxoma is more common in males with a bimodal age distribution, and its outcomes seem worse than usual cardiac myxomas. Increasing awareness of its clinical symptoms, early diagnosis, and complete myxoma resection before the presence of congestive heart failure symptoms are important in achieving excellent outcomes. A firm embolization blockade is needed to prevent myxoma recurrence.


Cardiac myxoma is the most common primary heart tumor, comprising 75% of all cardiac tumors [1]. The prevalence of cardiac myxoma ranges from 0.001 to 0.03% in the general population in several autopsy series [1, 2]. Cardiac myxoma is more common in females than males [1]. Cardiac myxoma can affect in some area in the heart such as the left atrium (75%), right atrium (15–20%), left ventricle (3–4%), and right ventricle (3–4%) [3]. The majority of cardiac myxomas are found in left atrial chambers, although it arises from cardiac valves in some cases, which are known as valvular myxoma [4, 5]. Mitral valve myxoma is the most common valvular myxoma, followed by tricuspid, aortic, and pulmonary valve myxoma [4, 5]. Valvular myxoma may have different characteristics from myxoma in the cardiac chamber due to its vital position and valvular involvement [6, 7].

Myxoma presentations can be categorized into cardiac obstructive symptoms (e.g., syncope, palpitation), constitutional symptoms (e.g., weight loss, low-grade fever), and embolic symptoms [8]. Symptoms depend on the size, location, mobility, invasiveness, and friability of the tumor [9]. Theoretically, a tumor in small orifices, such as the pulmonary valve, causes more severe manifestations of cardiac obstructions than tumors in larger chambers, such as the atria or ventricles. Additionally, the small diameter of the pulmonary orifice creates higher blood velocity that potentially leads to tumor dislodgement, causing acute pulmonary emboli and sudden death. Moreover, valvular attachment or infiltration itself may damage pulmonary valvular structures and require different treatment (e.g., valve replacement). Thus, the clinical characteristics of pulmonary valve myxoma, as well as its outcome, are probably different from other types of cardiac myxoma. However, little is known about pulmonary valve myxoma, and information is mostly sourced from case reports. Aggregated case reports or series show similar results to a systematic review of clinical studies in the setting of extremely rare diseases [10]. Aggregated evidence will provide a better understanding of this disease, thereby improving clinical outcomes. This systematic review aims to describe the clinical characteristics, management, and outcomes of pulmonary valve myxoma in published case reports.


The present review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 [11]. No ethical approval was required as no patients directly participated in this study and all the used data have already been published.


We performed a systematic search on case reports and a case series of pulmonary valve myxomas that described individual patient data. A pulmonary valve myxoma is defined as a cardiac myxoma that is partially or fully attached to any part of the pulmonary valve. Studies reporting indirect valve destruction due to myxoma that is not attached to the pulmonary valve or mobile tumors are excluded. The publication year has no limitation. Any studies written in languages other than English, those with no available full text and with nonhuman subjects were excluded. Duplicate articles were resolved before the title and abstract screening.

Search strategy and selection of studies

We conducted a comprehensive systematic database search on August 23, 2022, in PubMed, ScienceDirect, Scopus, Springer, and ProQuest. Relevant articles may be included by manual search or bibliography search to increase the coverage of this extremely rare case. The keyword “pulmonary valve myxoma” was used in the search. Titles and abstracts of the articles to identify potentially eligible studies were independently screened for full-text review.

Article extraction

We independently extracted relevant articles from the included studies using a structured and standardized form. The following information was extracted: first authors’ name, publication year, and country, patients’ age, gender, presenting symptoms and signs, murmur types, comorbidities or significant medical history, imaging modalities used, electrocardiogram (ECG) changes, histopathology examination, primary valve involvement, tumor size, complications, valvular status, management, and follow-up results.

Quality assessment

We independently assessed the risk of bias in included studies using the Joanna Briggs Institute (JBI) critical appraisal checklist for case reports and cases [12, 13]. The result of the bias assessment using the JBI checklist was presented as a checklist instead of an accumulated score [12].

Statistical analysis

Meta-analysis could not be performed because this systematic review includes an extremely rare disease based on published cases. However, the extracted data from the cases were put on a sheet and then quantitatively analyzed using descriptive statistics. Similar findings of variables, such as clinical presentation, ECG findings, recurrence, and mortality, are grouped to evaluate their frequency. For example, we tabulated the reported ECG examinations, such as right bundle branch block (RBBB) and right axis deviation (RAD). Then, we stated that RBBB was found in 50% of reported ECG cases if 3 RBBB was found in 6 reported ECG examinations.


Study selection

The search result in 2237 records, of which 1065 are duplicates. After title and abstract screening, 1130 articles were excluded. This systematic review included 9 published articles [14,15,16,17,18,19,20,21,22] after the full-text assessment. PRISMA flow diagram (Fig. 1) presents the process of study selection and the reasons for exclusion. A study is excluded as it is located just beneath the pulmonary annulus (not attached) [23].

Fig. 1
figure 1

PRISMA flow of study selection

Quality assessment

All included case reports were assessed using a JBI critical appraisal checklist for case reports. The summarized critical appraisal checklist shows that the risks are generally low (Supp. 1) in all case reports, although we do not define the criteria for low-risk bias of the study based on the total score.

Study characteristics

This systematic review of published cases included 9 case reports [14,15,16,17,18,19,20,21,22] (Table 1). Out of 9 cases, none of case series of pulmonary valve myxoma was found, indicating the rarity of this disease. The year of published case reports ranged from 1963 to 2022, of which 80% were published in the last 15 years. Most of the published cases are from Asia (6 cases), followed by America (2 cases) and Europe (1 case).

Table 1 Demographics, presentation, comorbidities, and diagnosis of pulmonary valve myxoma

Clinical characteristic

The range of patient age was 2 months to 82 years, with a median of 57 years. The age distribution shows that pulmonary valve myxoma is the most prevalent in pediatric and geriatric populations, with no case observed in ages 20 to 55 years (Table 1). All the cases have been confirmed by histopathology examinations. The male-to-female ratio is 5:4.

Two patients are asymptomatic, in which diagnosis was incidentally established. Additionally, a murmur is revealed in a patient after she is brought to a doctor due to a common cold, which is then diagnosed after an echocardiography examination [15]. Cardiovascular symptoms, such as palpitation, dyspnea, chest pain, syncope, cyanosis, and heart failure, are present in 5 cases (Table 1) [17, 18, 20,21,22]. Constitutional symptoms are observed in 4 cases [14, 16, 21, 22], of whom 2 had cardiovascular symptoms [21, 22]. Embolic symptoms were not observed in this review. Murmur is present in 5 cases, where it is best heard in the pulmonary valve area during the systolic phase (Table 1) [14,15,16, 20, 22]. Comorbidities varied between the cases.

Echocardiography, specifically trans-thoracal echocardiography, is the most common primary imaging modality used to diagnose myxoma (7 cases), followed by computed tomography (CT) scan (4 cases), magnetic resonance imaging (MRI) (3 cases), and angiography (1 case) (Table 2). Electrocardiography is abnormal in three of seven examinations, commonly presented as right-sided overload, indicated by right ventricle hypertrophy (RVH), RBBB, or right atrial enlargement (RAE) [14, 22]. Additionally, a complete heart block was observed; however, the patient already has it before the myxoma. Evidence and explanation showing complete heart block as the consequence of pulmonary valve myxoma are lacking.

Table 2 Tumor location, size, valvular status, complication, surgical procedures, and outcomes

Tumor diameter ranged from 8 to 40 mm. The tumor is attached to pulmonary cusps (7 cases) [14, 17,18,19,20,21,22], annulus (1 case) [15], and both (1 case) [16] (Table 2). Tumor extension was observed in all cases: RV (6 cases) [14,15,16,17, 19, 22], pulmonary artery (PA) (2 cases) [20, 21], or both (1 case) [18]. All reported studies show an abnormal pulmonary valve structure. Myxoma excision was performed in all cases. Additionally, other procedures were performed, including right ventricular outflow tract (RVOT) reconstruction (3 cases), valve replacement (2 cases), valve ring dilatation (1 case), and PA reconstruction (2 cases). Histopathology reveals an infected pulmonary valve myxoma in one case [16]. The youngest [22] and oldest [18] patients are deceased out of 9 cases. The youngest case is a 2-month-old male infant that has congestive heart failure symptoms, significant stenosis, and mild condition of Eisenmenger syndrome, which could be attributed to the severe RVOT obstruction. His condition has deteriorated following cardiac angiography; therefore, he undergoes surgical intervention that is relatively disadvantageous regarding the tumor size and condition. He passed away 7 h postoperatively [22]. The oldest case is an 82-year-old female with a large-sized myxoma that clumped all three pulmonary cusps and caused significant PA stenosis. Her myxoma surgery is uneventful, but recurrence occurred in her artificial pulmonary valve in 1-year follow-up. Surgery is not performed due to her poor general condition, and she died of right heart failure [18]. Recurrence occurred in one of the three reported cases.



Pulmonary valve myxoma is an extremely rare type of cardiac myxoma with only 9 case reports eligible from 5 databases without time limitation, emphasizing this rarity of the disease. Interestingly, pulmonary valve myxoma has a bimodal age-distribution fashion, with pediatric and elderly patients dominating the cases. In contrast, cardiac myxoma is prevalent in geriatric and adult populations, whereas pediatric cardiac myxoma is uncommon [1, 4, 5, 24, 25]. Pediatric cardiac myxoma may arise from residual primitive endocardial tissue [22]. Data from published literature revealed that pulmonary valve myxoma may be dominated by males, whereas cardiac myxoma is dominated by females [1, 4, 5, 24, 25]. However, the gender prevalence in pulmonary valve myxoma remains questionable because of the small sample size.

Clinical presentation and diagnostic approach

Pulmonary valve myxoma in very young children is characterized by low body weight and systolic murmur at the left sternal border. The murmur may be heard during birth [22]. Both cases show right heart hypertrophy in ECG examination, consisting of RVH, RBBB, and RAE, which are probably caused by severe pulmonary stenosis [14, 22]. Severe pulmonary stenosis may be caused by smaller tumor size and pulmonary orifice ratio in very young children than in adults. Congestive heart failure is present in severe cases and ends up with mortality [22].

Cardiovascular symptoms are the most common specific presentation. This finding is in concordance with previous studies that show cardiac symptoms as the most common specific symptom, present in 47–66% of cases, with heart failure as the two commonest manifestations [4, 5, 8]. Heart failure symptoms are observed in only less than half of the patients with cardiovascular symptoms, and both cases end with death. This may be due to low resistance in the pulmonary circulation; hence, allowing lower pressure is needed to eject flow from the right ventricle to the pulmonary circulation and RV for compensation, such as by RV hypertrophy [14, 22]. Congestive heart failure seems to be a sign of decompensated RV and severe disease in pulmonary valve myxoma. Constitutional symptoms, such as fever, malaise, and weight loss, are probably caused by pro-inflammatory cytokines (e.g., interleukin-1) secreted by myxoma cells [9]. Children with pulmonary valve myxoma all present with poor intake and vomiting; therefore, the myxoma could contribute to growth failure in children. An embolic event was not reported. Embolic symptoms are variably reported in previous studies, ranging from 6 to 41% [4, 5, 8, 25]. Additionally, one-third of patients are asymptomatic (including a patient with a common cold) and diagnosed incidentally. This finding is in concordance with previous studies that show that asymptomatic cases range from 17 to 46%, and the majority are diagnosed by incidental radiology findings [8].

Murmur is a common clinical sign in pulmonary valve myxoma and becomes a precious clue of cardiac-involving disease, especially in patients with no or unspecific symptoms. A murmur is often heard at the pulmonary valve area during the systolic phase in pulmonary valve myxoma. This probably resulted from stenosis due to tumor obstruction during pulmonary orifice opening. Pulmonary stenosis increases RV pressure and causes right-sided heart overload as well as heart failure in the long term. Right ventricle overload causes tricuspid insufficiency, which is observed in two patients [14, 18]. Perforation of RV by a temporary pacemaker may occur due to increased RV pressure or overload [17]. Additionally, an increase in RV may cause tricuspid abnormality, as shown by a murmur in the tricuspid area [14]. Moreover, the most common ECG abnormalities are right-sided heart overload and RBBB [14, 22]. However, ECG seems an insensitive modality and not specific. In general, other laboratory examinations are not sensitive and specific [8].

Transthoracic echocardiography is the most common primary modality to diagnose pulmonary valve myxoma, including asymptomatic cases. Angiography has been the modality of choice before echocardiography is largely introduced in hospitals. Currently, echocardiography is an affordable, noninvasive, and preferred modality to diagnose cardiac myxoma [26, 27]. Echocardiography can delineate cardiac tumor morphology, size, extension, and attachment as well as its hemodynamic manifestation [28]. Transthoracic echocardiography sensitivity can reach up to 90% and even higher in transesophageal echocardiography. However, differentiating between myxoma, thrombus, and vegetation in the pulmonary valves may be difficult. MRI or contrast-enhanced CT scan can be used in doubtful cases to evaluate myxoma complications.

Management and outcomes

Surgery is the definitive treatment of cardiac myxoma and should be performed without delay after establishing its diagnosis to avoid sudden death. Sudden death can be caused by complete tumor obstruction or dislodgement as well as a potential embolic manifestation in pulmonary valve myxoma. Even small tumor fragment dislodgement can cause significant thrombus and cause a fatal acute pulmonary embolus.

The tumor can be attached to pulmonary cusps or annulus; both conditions cause cusps abnormality in all cases. Tumor excision may involve pulmonary cusps and require valve replacements in several cases because of valvular involvement. All tumors have extended to the surrounding tissue. Excision should involve a large margin of tumor extension as well as its surrounding tissues because the residual tissue may cause recurrence. Thus, additional surgical procedures are needed in almost all cases. Valve replacement has been reported in 22% of cases. In contrast, valve replacement is an additional procedure that is needed only in < 5% of non-valvular myxoma excision [4, 29]. Anticipation of complex surgical procedures may be needed in pulmonary valve myxoma management.

The mortality of pulmonary valve myxoma is considerably high compared to other cardiac myxomas [4, 5, 30]. This may be caused by valvular involvement as well as its narrow orifice location. However, extreme age seems to contribute to high mortality in pulmonary valve myxoma, regarding death cases involving the youngest and oldest patients. Notably, this systematic review did not directly compare the outcomes between pulmonary valve myxoma and other types of myxoma.

Surgery is a definitive treatment of cardiac myxoma, and its outcome is generally excellent with a mortality range of 0.7–3.1% [4, 5, 30]. High mortality in pulmonary valve myxoma in the current review is caused by disadvantageous general conditions to perform surgery, especially CHF, and is complicated by significant pulmonary stenosis. Additionally, a person with extreme age (extremely young or old age) has relatively unstable hemodynamics and higher mortality postoperatively [31]. The location of the pulmonary valve myxoma itself is important, and additional surgical procedure, such as valve excision or adjacent tissue excision, is more often required than in the usual cardiac myxoma. Additionally, recurrence is observed in one case during a year follow-up time, specifically in the second death case, out of three reported data. This percentage is considerably high as the myxoma recurrence rate is commonly low (< 5% in < 5 years of follow-up) [4, 5, 30, 32]. The high recurrence percentage in pulmonary valve myxoma may be caused by the residual tumor tissue, regarding its vital position and extension to RVOT as well as PA, making the excision area become strictly limited and the margin indistinguishable. Cytotransplantation or systemic embolization can also cause myxoma recurrence [18]. Firm embolization blockade (e.g., gauze) can be used to prevent tumor cell embolization to PA.

Study limitation

The limitation of this systematic review is that it included case reports only with a small number of participants. Cordero et al. [10] reported that aggregating case reports showed similar results to the meta-analysis of a clinical study in the aspect of case reports. A systematic review of published case reports is useful in the setting of rare diseases [33, 34]. The small number of included cases is due to the rarity of this disease, and we anticipated it by not performing statistical analytics that could potentially lead to bias. Additionally, this systematic review did not directly compare the outcomes between pulmonary valve myxoma and other-type myxomas. Instead, the data is presented descriptively, and the reader should be cautious with the conclusion because of the small sample size.


Pulmonary valve myxoma is an extremely rare disease. It has a bimodal age distribution in pediatric and geriatric populations, with a male majority. Pulmonary stenosis murmur is often a clue for cardiac involvement, especially in asymptomatic or unspecified symptoms. Echocardiography is a noninvasive recommended modality to diagnose pulmonary valve myxoma. Pulmonary valve myxoma considerably has a relatively high number of (1) valves and tissue reconstructions (2), recurrence, and (3) mortality. Early diagnosis and definitive treatment before the presentation of congestive heart failure symptoms may be important in achieving excellent outcomes.

Availability of data and materials

All data are available in the manuscript and separated files as supplementary.



Cyclic adenosine monophosphate


Computed tomography


Individual patient data


Joanna Briggs Institute


Magnetic resonance imaging


Pulmonary artery


Protein kinase A


Preferred Reporting Items for Systematic Reviews and Meta-Analyses


Right atrial enlargement


Right bundle branch block


Right ventricle


Right ventricle hypertrophy


Right ventricular outflow tract


  1. Isogai T, Yasunaga H, Matsui H, Tanaka H, Hisagi M, Fushimi K. Factors affecting in-hospital mortality and likelihood of undergoing surgical resection in patients with primary cardiac tumors. J Cardiol. 2017;69(1):287–92.

    Article  PubMed  Google Scholar 

  2. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117(10):1027–31.

    CAS  PubMed  Google Scholar 

  3. Islam AKM. Cardiac myxomas: a narrative review. World J Cardiol. 2022;14(4):206–19.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Perek B, Misterski M, Stefaniak S, Ligowski M, Puślecki M, Jemielity M. Early and long-term outcome of surgery for cardiac myxoma: experience of a single cardiac surgical centre. Kardiol Pol. 2011;69(6):558–64.

    PubMed  Google Scholar 

  5. Karabinis A, Samanidis G, Khoury M, Stavridis G, Perreas K. Clinical presentation and treatment of cardiac myxoma in 153 patients. Med (United States). 2018;97(37):0–5.

    Google Scholar 

  6. Vijayvergiya R, Krishnappa D, Kasinadhuni G, Panda P, Rana SS, Dass A. Cardiac myxoma of mitral valve: an uncommon presentation. IHJ Cardiovasc Case Rep. 2018;2(2):77–8.

    Article  Google Scholar 

  7. Grubb KJ, Jevremovic V, Chedrawy EG. Mitral valve myxoma presenting with transient ischemic attack: a case report and review of the literature. J Med. 2018;363(13):1920–8.

    Google Scholar 

  8. Lee PT, Hong R, Pang PYK, Chua YL, Ding ZP. Clinical presentation of cardiac myxoma in a Singapore national cardiac centre. Singapore Med J. 2021;62(4):195–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Acebo E, Val-Bernal JF, Gómez-Román JJ, Revuelta JM. Clinicopathologic study and DNA analysis of 37 cardiac myxomas: a 28-year experience. Chest. 2003;123(5):1379–85.

    Article  PubMed  Google Scholar 

  10. Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14(1):1–11.

    Article  Google Scholar 

  11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.

    Google Scholar 

  12. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: systematic reviews of etiology and risk. In: Munn Z, editor. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017. Available from:

  13. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Diet Suppl. 2013;10(4):381–90.

    Article  PubMed  Google Scholar 

  14. Yakirevich V, Glazer Y, Ilie B, Vidne B. Myxoma of the pulmonary valve causing severe pulmonic stenosis in infancy. J Thorac Cardiovasc Surg. 1982;83(6):936–7.

    Article  CAS  PubMed  Google Scholar 

  15. Kumagai K, Sai S, Endo M, Tabayashi K. Right ventricular myxoma obstructing the pulmonary artery during early childhood. Gen Thorac Cardiovasc Surg. 2008;56(7):351–3.

    Article  PubMed  Google Scholar 

  16. Yang EH, Zadeh AA, Chung J. A superinfected pulmonary valve myxoma. J Am Coll Cardiol. 2010;56(24):2045.

    Article  PubMed  Google Scholar 

  17. Sargar S, Agrawal N, Mishra P, Aironi B. Pulmonary valve myxoma with complete heart block—a rare case report. Indian J Thorac Cardiovasc Surg. 2014;30(4):292–4.

    Article  Google Scholar 

  18. Tanabe S, Yano K, Mizunaga T, Kawamura Y, Takamori A, Yamada N, et al. Pulmonary valve myxoma requiring pulmonary valve replacement: a case report. Surg Case Reports. 2022;8(1):1–5.

    Article  Google Scholar 

  19. Roux O, Tinguely F, Barras J, Prêtre R, Goy J. Myxoma of the pulmonary valve. Cardiovasc Med. 2017;20(05):136–7.

    Article  Google Scholar 

  20. Tansel T, Helin E, Gok E. Primary myxoma of the pulmonary artery. J Card Surg. 2011;26(3):2860287.

    Article  Google Scholar 

  21. Mai XL, Fan HJ, Li BX, Zhu B. Primary pulmonary artery myxoma: a rare case. Clin Imaging. 2013;37(1):159–62.

    Article  PubMed  Google Scholar 

  22. Catton RW, Guntheroth WG, Reichenbach DD. A myxoma of the pulmonary valve causing severe stenosis in infancy. Am Heart J. 1963;66(2):248–52.

    Article  CAS  PubMed  Google Scholar 

  23. Yamaguchi A, Sakamoto H, Mathis BJ, Watanabe Y, Kato H, Hiramatsu Y. Right ventricular outflow tract myxoma with absent pulmonary valve. In: The Heart Surgery Forum. Forum Multimedia Publishing; 2022. p. 2–4.

  24. Wang J-G, Wang B, Hu Y, Liu J-H, Liu B, Liu H, et al. Clinicopathologic features and outcomes of primary cardiac tumors: a 16-year-experience with 212 patients at a Chinese medical center. Cardiovasc Pathol. 2018;33:45–54. [cited 2022 Jul 11]. Available from:

    Article  CAS  PubMed  Google Scholar 

  25. Rahman MT, Ali MZ, Kabir MH, Azam SA, Majumder A, Rahman A, et al. Clinical profile of cardiac myxoma: 11 years’ experience of 90 cases. Bangladesh Hear J. 2016;31(1):18–22.

    Article  Google Scholar 

  26. Bordalo ÁDB, Alves I, Nobre ÂL, Silva F, Lemos A, Serpa C, et al. New clinical aspects of cardiac myxomas: a clinical and pathological reappraisal. Rev Port Cardiol (English Ed). 2012;31(9):567–75.

    Article  Google Scholar 

  27. Samanidis G, Khoury M, Balanika M, Perrea DN. Current challenges in the diagnosis and treatment of cardiac myxoma. Kardiol Pol. 2020;78(4):269–77.

    Article  PubMed  Google Scholar 

  28. Mankad R, Herrmann J. Cardiac tumors: echo assessment. Echo Res Pract. 2016;3(4):R65-77.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bortolotti U, Maraglino G, Rubino M, Santini F, Mazzucco A, Milano A, et al. Surgical excision of intracardiac myxomas: a 20-year follow-up. Ann Thorac Surg. 1990;49(3):449–53.

    Article  CAS  PubMed  Google Scholar 

  30. Dell’Amore A, Albertini A, Lamarra M. Twenty years experience in oncologic surgery for primary cardiac tumors. G di Chir. 2013;34(4):106–11.

    Google Scholar 

  31. Fecho K, Lunney AT, Boysen PG, Rock P, Norfleet EA. Postoperative mortality after inpatient surgery: incidence and risk factors. Ther Clin Risk Manag. 2008;4(4):681–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Luo C, Zhu J, Bao C, Ding F, Mei J. Minimally invasive and conventional surgical treatment of primary benign cardiac tumors. J Cardiothorac Surg. 2019;14(1):1–7.

    Article  Google Scholar 

  33. Denny E. Metasummary is a useful way of synthesising quantitative and qualitative data. BJOG An Int J Obstet Gynaecol. 2019;126(1):22.

    Article  CAS  Google Scholar 

  34. Herber OR, Kastaun S, Wilm S, Barroso J. From qualitative meta-summary to qualitative meta-synthesis: introducing a new situation-specific theory of barriers and facilitators for self-care in patients with heart failure. Qual Health Res. 2019;29(1):96–106.

    Article  PubMed  Google Scholar 

Download references


We thank the staff of the Cardiology and Vascular Medicine Departments, Faculty of Medicine, Universitas Airlangga, for their support for the writing of this study.



Author information

Authors and Affiliations



Conceptualization, PBTS, CDKW, and YHO; data curation, PBTS, ARJ, and IFR; formal analysis, MJA, AG, and IFR; investigation, MYA, PBTS, ARJ, and HS; methodology, CDKW and AG; project administration, PBTS, IFR, and ARJ; resources, PBTS, IFR, and ARJ; software, HS; supervision, CDKW, AG, YHO, and MYA; validation, CDKW, YHO, HS, and AG; visualization, PBTS and ARJ; writing—original draft, PBTS, IFR, and MYA; and writing—review and editing, all authors. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Citrawati Dyah Kencono Wungu or Hendri Susilo.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Bias risk assessment of included studies using Joanna Briggs Institut checklist.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saputra, P.B.T., Jannah, A.R., Rofananda, I.F. et al. Clinical characteristics, management, and outcomes of pulmonary valve myxoma: systematic review of published case reports. World J Surg Onc 21, 99 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Pulmonary valve myxoma
  • Cardiac tumor
  • Cardiovascular disease
  • Clinical characteristics
  • Systematic review